Straits Times Index
3,318.47 +10.57 (+0.32%) Nikkei
39,103.22 +486.12 (+1.26%) Hang Seng
18,911.99 -283.61 (-1.48%) FTSE 100
8,373.55 +3.22 (+0.04%) Bitcoin USD
69,525.79 -297.04 (-0.43%) CMC Crypto 200
1,515.39 +12.73 (+0.85%)
Fractyl Health, Inc. (GUTS)
After hours:
| Previous close | 7.28 |
| Open | 7.35 |
| Bid | 7.58 x 100 |
| Ask | 7.69 x 100 |
| Day's range | 7.09 - 7.67 |
| 52-week range | 5.75 - 14.50 |
| Volume | |
| Avg. volume | 300,116 |
| Market cap | 364.974M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
Fractyl Health Presents Compelling Preclinical Data from Single-Administration GLP-1 Pancreatic Gene Therapy Rejuva® at Digestive Disease Week 2024
Results showed single-administration GLP-1 pancreatic gene therapy candidate reduced liver weight by 42% (p<0.01) and liver triglycerides by 67% (p<0.0001) compared to placebo two months after administration Data also demonstrated reductions of 36% in total cholesterol and 51% in low density lipoprotein (LDL) cholesterol (both, p<0.0001) compared to placebo two months after administration New results highlight potential for profound, durable, and broad metabolic benefit that can be achieved from
- GlobeNewswire
Fractyl Health Reports First Quarter 2024 Financial Results and Provides Business Updates
Initiation of Remain-1 pivotal study for weight maintenance in patients with obesity after discontinuation of GLP-1 based drugs expected in the second half of 2024 Topline data from Revitalize-1 pivotal study in patients with inadequately controlled T2D anticipated in the fourth quarter 2024 Update from real-world Germany registry study of Revita in patients with T2D at DDG Annual Meeting Appointed Adrian Kimber as Chief Commercial Officer to lead Revita launch readiness activities Conference ca
- GlobeNewswire
Fractyl Health Presents Clinical Update on Revita® German Real-World Registry for Patients With Advanced Type 2 Diabetes (T2D)
First 14 participants with at least six months of follow up continue to demonstrate sustained improvements in blood glucose and weight with reduction in T2D medication utilization after a single Revita treatment No device- or procedure-related serious adverse events have been observed to date in any registry participant BURLINGTON, Mass., May 13, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (Nasdaq: GUTS) (the “Company”), a metabolic therapeutics company focused on pioneering new approaches for
